Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aveo Pharmaceuticals and Astellas Pharma have announced that superiority results of tivozanib over sorafenib from TIVO-1, a global, randomized Phase 3 clinical trial, in patients with advanced renal cell carcinoma (RCC).
Subscribe to our email newsletter
Tivozanib is a potent, selective and continuous inhibitor of all three vascular endothelial growth factor (VEGF) receptors that are designed to optimize VEGF blockade while minimizing off-target toxicities.
The drug, which is an oral, once-daily, investigational tyrosine kinase inhibitor, has reported positive top-line results from a Phase 3 clinical study in advanced renal cell carcinoma.
TIVO-1 is the first registration study in first-line RCC that is comparing an investigational agent against an approved VEGF therapy.
Tivozanib demonstrated superior data compared to sorafenib in the primary endpoint of progression-free survival (PFS).
Tivozanib showed a statistically significant improvement in PFS with a median PFS of 11.9 months compared to a median PFS of 9.1 months for sorafenib in the overall study population